PCSK1 and Parkinson disease: In addition, NEC-1 (i) blocked oligodendrocyte death, microglial inflammation and axonal degeneration in ALS models [16,57,58], (ii) protected against oligodendrocyte death in MS models [59], (iii) reduced the β amyloid burden, levels of inflammatory cytokines, and memory deficits in an AD model [60], and (iv) attenuated MPTP-induced dopaminergic neuronal loss in a PD model [61].